Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1993-12-28
1995-05-16
Richter, Johann
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
549229, A61K 31335, C07D49308
Patent
active
054161061
ABSTRACT:
The present invention relates to 7-[carboxyalkyl or alkenyl]-6-[alkyl or alkenyl]-3-oxo-2,4-dioxobicyclo[3.2.1 ] octanes and derivatives thereof. In particular, hydroxyl, nitro, amino, amido, azido, oxime, thiol, ether and thiol ether derivatives of said carboxy group are contemplated. In particular, 7-[6-carboxy-2-hexenyl]-6-[3-hydroxy-1-octenyl] of 3-oxo-2,4-dioxobicyclo-[3.2.1] octane and derivatives thereof are disclosed. These compounds are useful as ocular hypotensives and as (a) thromboxane mimetics for the prevention of hemorrhaging as follows:, during surgery; tooth extraction; hemorrhaging associated with gastro-intestinal diseases and conditions such as hemorrhoids, inflammatory bowel diseases and gastric and peptic ulcers; as a result of stroke; as a complication in retinal diseases resulting in impaired vision and associated with menstruation, childbirth and uterine dysfunction and (b) selective vasoconstrictors for treating systemic hypotension, e.g. in restoring normal blood pressure in hemorrhagic, anaphylactic, or septic shock victims; to provide local anti-inflammatory effects in the eye, skin and nose; to limit plasma exudation in burns, etc. and optimizing blood born delivery of drugs and diagnostics in encapsulating vehicles.
REFERENCES:
patent: 4599353 (1986-07-01), Bito
patent: 4994274 (1991-02-01), Chan et al.
patent: 5034413 (1991-07-01), Chan et al.
Starr. M. S., "Further Studies on the Effect of Prostalgnadin on Intraocular Pressure in the Rabbit", Exp. Eye Research, (1971), 11, pp. 170-177.
Bito, L. Z., "Prostaglandins, Other Eicosanoids, and Their Derivatives as Potential Antiglaucoma Agents," Applied Pharmacology in the Medical Treatment of Glaucomas Drance, S. M. and Neufeld, A. H. eds., New York, Grune & Stratton, (1984), pp. 477-505.
Nilsson, et al., "PGF.sub.2.alpha. Increases Uveoscleral Outflow", Invest. Ophthalmol. Vis. Sci. (suppl), 284, (1987).
Siebold, et al., "Esterified prostaglandin shows `potent` promise", Prodrug 5 3, (1989).
Bito, L. Z., "Prostaglandins, Old Concepts and New Perspectives", Arch. Ophthalmol. 105, 1036, (1987).
Coleman, R. A., et al., Comparison of the Actions of U-46619, A Prostaglandin H2-Analogue, with Those of Prostaglandin H2 and Thromboxane A2 on some isolated Br. J. Pharmacol. 73:773-778 (1981).
Burk et al., Tetrahedron Letters (1993), 34(3), 395-8.
Burk Robert M.
Krauss Achim H.
Woodward David F.
Allergan Inc.
Baran Robert J.
Lambert Howard R.
Peabody John
Richter Johann
LandOfFree
7-[carboxyalkyl or alkenyl]-6-[alkyl or alkenyl]3-oxo-2,4-dioxob does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 7-[carboxyalkyl or alkenyl]-6-[alkyl or alkenyl]3-oxo-2,4-dioxob, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 7-[carboxyalkyl or alkenyl]-6-[alkyl or alkenyl]3-oxo-2,4-dioxob will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-637989